References: 1.
Zander M,
et al.
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and ß-cell function
in type 2 diabetes: a parallel-group study.
Lancet
. 2002;359:824-830.
2.
Toft-Nielsen M-B,
et al.
Determinants of the Impaired Secretion
of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients.
J Clin Endocrinol Metab
. 2001;86(8):3717-3723.
3.
Kjems LL,
et al.
The Influence of GLP-1
on Glucose-Stimulated Insulin Secretion. Effects on ß-Cell Sensitivity in Type 2 and Nondiabetic Subjects.
Diabetes
. 2003;52:380-386.
Novo Nordisk (Pty) Ltd. Reg. No.: 1959/000833/07. PO Box 783155, Sandton, 2146. Tel: (011) 202 0500 Fax: (011) 807 7989
NN/DUO/4244/09/10/VER1
Diabetes |
A whole new perspective
Are you
looking at
every part
of diabetes?
You might be missing GLP-1.
It’s a
natural hormone that helps regulate glucose
metabolism. It also slows gastric emptying,
promotes satiety, and plays a significant role
in beta-cell function.
1
Its multiple actions
throughout the body are critical in diabetes.
Unfortunately, your patients might be
missing GLP-1, too.
Many people with
type 2 diabetes may have impaired GLP-1
secretion and impaired beta-cell response
to GLP-1.
2,3
This could contribute to the
pathogenesis of the disease.
1
Looking at the whole problem is the most
important part of understanding it. That’s why
Novo Nordisk is dedicated to ongoing research
and development in the management of
diabetes.
